- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00025064
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplant may be able to replace immune cells that were destroyed by chemotherapy.
PURPOSE: This phase II trial is studying how well combination chemotherapy regimens with or without radiation therapy or peripheral stem cell transplant works in treating children with Hodgkin's lymphoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Strahlung: Strahlentherapie
- Arzneimittel: Etoposid
- Arzneimittel: Vincristinsulfat
- Arzneimittel: Cisplatin
- Arzneimittel: Doxorubicinhydrochlorid
- Verfahren: Transplantation peripherer Blutstammzellen
- Arzneimittel: Melphalan
- Arzneimittel: Chlorambucil
- Arzneimittel: Dacarbazin
- Arzneimittel: Ifosfamid
- Arzneimittel: Procarbazinhydrochlorid
- Arzneimittel: Prednisolon
- Arzneimittel: Vinblastinsulfat
- Biologisch: Bleomycinsulfat
Detaillierte Beschreibung
OBJECTIVES:
- Determine whether the current survival figures are maintained and long-term sequelae of treatment are minimized in children or adolescents with stage I-III Hodgkin's lymphoma after receiving the following regimen, which reduces exposure to chemotherapy and radiotherapy: chlorambucil, vinblastine, prednisolone, and procarbazine (ChIVPP) and doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD) with etoposide, prednisolone, ifosfamide, and cisplatin (EPIC), radiotherapy, high-dose melphalan, and/or autologous peripheral blood stem cell transplantation (APBSCT).
- Determine whether the survival figures are improved in children or adolescents with stage IV Hodgkin's lymphoma or inadequate response to initial therapy after receiving ChIVPP and ABVD with EPIC, radiotherapy, high-dose melphalan, and APBSCT.
OUTLINE: This is a multicenter study. Patients are assigned to 1 of 3 treatment groups based on disease status.
- Group 1 (stage I disease): All patients with mixed cellularity and younger patients with any subtype are assigned to subgroup A. Older patients without mixed cellularity are assigned to subgroup A or B based on the decision of the physicians and patients/parents. Subgroup A: Patients receive 2 courses of the hybrid regimen. One course of the hybrid regimen comprises regimen ChIVPP followed by regimen ABVD. Regimen ChIVPP comprises vinblastine IV on days 1 and 8 and oral chlorambucil, oral procarbazine, and oral prednisolone (PRDL) daily on days 1-14. Regimen ABVD comprises doxorubicin IV over 6 hours, bleomycin IV over 15-30 minutes, vincristine IV, and dacarbazine IV over 15 minutes on days 1 and 14. Patients with relapsed disease receive etoposide IV over 1 hour on days 1-4, oral PRDL and ifosfamide IV over 1 hour on days 1-5, and cisplatin IV over 24 hours on day 10 (EPIC). Treatment with EPIC continues every 3 weeks for a total of 6 courses. Patients then undergo radiotherapy. Patients with poor response after radiotherapy receive consolidation with high-dose melphalan (L-PAM) IV over 30-90 minutes, followed at least 12 hours later by autologous peripheral blood stem cell transplantation (APBSCT) (if there is no bone marrow involvement at the time of relapse). Subgroup B: Patients not in subgroup A may either receive chemotherapy as outlined or radiotherapy depending on clinician and patient discussion. Patients with relapsed disease after radiotherapy receive 3 courses of the hybrid regimen. If relapse occurs outside the initial radiotherapy field, then further radiotherapy is administered.
- Group 2 (stage II or III disease): Patients receive 3 courses of the hybrid regimen. Patients with relapsed disease receive 4 courses of EPIC. Patients with complete remission (CR) or good partial remission (GPR) after the fourth course of EPIC receive 2 additional courses of EPIC followed by radiotherapy. Patients without CR or GPR after the fourth course of EPIC undergo radiotherapy followed by L-PAM and APBSCT as in group 1, subgroup A.
- Group 3 (stage IV or inadequate response to initial therapy): Patients receive 2 courses the hybrid regimen. Patients with CR or GPR after the second course of ABVD are assigned to subgroup C. Patients without CR or GPR after the second course of ABVD are assigned to subgroup D. Subgroup C: Patients receive 2 additional courses of the hybrid regimen. Patients with relapsed disease after the fourth course of ABVD receive 4 courses of EPIC followed by radiotherapy, L-PAM, and APBSCT as in group 1, subgroup A. Subgroup D: Patients receive 4 courses of EPIC followed by radiotherapy, L-PAM, and APBSCT as in group 1, subgroup A.
Patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 260 patients (75 with stage I disease, 150 with stage II or III disease, and 35 with stage IV disease) will be accrued for this study within 5 years.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Dublin, Irland, 12
- Our Lady's Hospital For Sick Children
-
-
-
-
England
-
Birmingham, England, Vereinigtes Königreich, B4 6NH
- Birmingham Children's Hospital
-
Bristol, England, Vereinigtes Königreich, BS2 8BJ
- Bristol Royal Hospital for Children
-
Cambridge, England, Vereinigtes Königreich, CB2 2QQ
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
-
Leeds, England, Vereinigtes Königreich, LS9 7TF
- Leeds Cancer Centre at St. James's University Hospital
-
Leicester, England, Vereinigtes Königreich, LE1 5WW
- Leicester Royal Infirmary
-
Liverpool, England, Vereinigtes Königreich, L12 2AP
- Royal Liverpool Children's Hospital, Alder Hey
-
London, England, Vereinigtes Königreich, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
London, England, Vereinigtes Königreich, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Vereinigtes Königreich, WIT 3AA
- Meyerstein Institute of Oncology at University College of London Hospitals
-
Manchester, England, Vereinigtes Königreich, M27 4HA
- Central Manchester and Manchester Children's University Hospitals NHS Trust
-
Newcastle-Upon-Tyne, England, Vereinigtes Königreich, NE7 7DN
- Newcastle Upon Tyne Hospitals NHS Trust
-
Nottingham, England, Vereinigtes Königreich, NG7 2UH
- Queen's Medical Centre
-
Oxford, England, Vereinigtes Königreich, 0X3 9DU
- Oxford Radcliffe Hospital
-
Sheffield, England, Vereinigtes Königreich, S10 2TH
- Children's Hospital - Sheffield
-
Southampton, England, Vereinigtes Königreich, SO16 6YD
- Southampton General Hospital
-
Sutton, England, Vereinigtes Königreich, SM2 5PT
- Royal Marsden NHS Foundation Trust - Surrey
-
-
Northern Ireland
-
Belfast, Northern Ireland, Vereinigtes Königreich, BT12 6BE
- Royal Belfast Hospital for Sick Children
-
-
Scotland
-
Aberdeen, Scotland, Vereinigtes Königreich, AB25 2ZN
- Aberdeen Royal Infirmary
-
Edinburgh, Scotland, Vereinigtes Königreich, EH9 1LF
- Royal Hospital for Sick Children
-
Glasgow, Scotland, Vereinigtes Königreich, G3 8SJ
- Royal Hospital for Sick Children
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically proven Hodgkin's lymphoma
- Stage I-IV
- No posttransplantation Hodgkin's lymphoma
- Mediastinal syndrome allowed
PATIENT CHARACTERISTICS:
Age:
- Under 18 at diagnosis
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No other previously treated malignancy
- No DNA repair defect syndromes
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Martin Hewitt, MD, BSc, FRCP, FRCPCH, Queen's Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Entzündungshemmende Mittel
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Glukokortikoide
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Antineoplastische Mittel, hormonell
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Antineoplastische Mittel, Phytogen
- Topoisomerase-II-Inhibitoren
- Topoisomerase-Inhibitoren
- Antibiotika, antineoplastische
- Prednisolon
- Etoposid
- Ifosfamid
- Melphalan
- Doxorubicin
- Liposomales Doxorubicin
- Vincristin
- Dacarbazin
- Bleomycin
- Vinblastin
- Procarbazin
- Chlorambucil
Andere Studien-ID-Nummern
- CCLG-HD-2000-02
- CDR0000068901 (Registrierungskennung: PDQ (Physician Data Query))
- EU-20108
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
Klinische Studien zur Strahlentherapie
-
Alpha Tau Medical LTD.Noch keine RekrutierungBrustkrebs | Brustkrebs | Rezidivierender BrustkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Hauttumor | Kutane MetastasenFrankreich
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCNoch keine RekrutierungKopf-Hals-Plattenepithelkarzinom | PlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungProstata-AdenokarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutierungLungenkrebs | Wiederkehrender LungenkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.AbgeschlossenPlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaItalien
-
Alpha Tau Medical LTD.Aktiv, nicht rekrutierendHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael